Diligence memo · auto-generated · as of July 2, 2026

Judo Bio Inc.

Judo Bio Inc. looks fair against its niche peers and is quiet on financing cadence.

SourceRaising on rhythm with a 5.0× step-up on the last round — momentum worth tracking before it's priced in.

Businessfiled

Judo Bio Inc. operates in Biotechnology, based in CAMBRIDGE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Judo Bio Inc. has raised $55M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $25M on 2022-11-04.

Most recent recorded round closed around 2024-07-31.

Valuation (modeled)modeled

Provath models Judo Bio Inc. at approximately $172M (range $50M–$303M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.03× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era. Within the normal band (103% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 7 months.

Last raise 23 mo ago; this sector typically re-raises about every 14 months.

Slightly overdue versus sector cadence.

The last round stepped up 5.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 83% of Biotechnology peers (4293 compared).

Modeled value ranks above 69% of those peers.

Closest niche peers: Mt McKinley Medical Holding Corp USA, YAP Therapeutics Inc, Pinteon Therapeutics, Inc., OncXerna Therapeutics, Ltd., EpiBiologics, Inc..

Peoplefiled

9 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.